SCHEMBL23494352

SCHEMBL23494352

Cc1nc(N)ncc1-c1cnccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
PIK3CA P42336 3/20 0.39
PIK3R1 P27986 2/20 0.39
MTOR P42345 1/20 0.39
DHFR P00374 1/20 0.39
HSP90AA1 P07900 2/20 0.38
MBOAT4 Q96T53 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
CYP1A2 P05177 1/20 0.37
ACHE P22303 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CB P42338 1/20 0.35
PI4KA P42356 1/20 0.35
PIK3CG P48736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15436242 0.81 DHFR (0.46) HTTRECQLALOX5APFEN1PIK3CA
Hydrochloric Acid SCHEMBL15436256 0.80 DHFR (0.45) HTTRECQLALOX5APFEN1PIK3CA
Hydrochloric Acid SCHEMBL15436275 0.80 DHFR (0.45) HTTRECQLALOX5APFEN1PIK3CA
SCHEMBL23494350 0.75 HTT (0.41) HTTRECQLPIK3CADHFRHSP90AA1
SCHEMBL10917626 0.73 ADORA1 (0.58) ALOX5APPIK3CAPIK3R1MTORACHE
SCHEMBL9957239 0.70 PIK3C3 (0.64) PIK3CAPIK3CDPIK3CGPI4KB
SCHEMBL7915364 0.70 MBOAT4 (0.47) HTTRECQLALOX5APFEN1PIK3CA
SCHEMBL9957523 0.70 LMNA (0.51) PIK3CAPIK3R1MTORKDM4EACHE
SCHEMBL3642814 0.69 CDK2 (0.38) ALOX5APFEN1PIK3CAPIK3R1MTOR
SCHEMBL30726498 0.69 ALOX5AP (0.49) HTTRECQLALOX5APFEN1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210179591-A1 NEW COMPOUNDS FOR USE AS A THERAPEUTICALLY ACTIVE SUBSTANCE AND IN PARTICULAR FOR USE IN THE TREATMENT OF TUMORS ETH ZURICH (CH) 2021-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179591-A1 NEW COMPOUNDS FOR USE AS A THERAPEUTICALLY ACTIVE SUBSTANCE AND IN PARTICULAR FOR USE IN THE TREATMENT OF TUMORS HNMT, MET, OGFR HTT 2179/4885RECQL 3307/4885ALOX5AP 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.